Washington Medicaid spending on GLP-1 drugs

How much did Washington Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $82.7 million for GLP-1 drugs paid through Washington Medicaid in 2025, across at least 111,202 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 98 rows of 281, so these figures are floors.

Pharmacies were reimbursed at least $24.9 million for GLP-1 drugs paid through Washington Medicaid in 2026 (quarter 1 only, as posted so far), across at least 30,841 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 22 rows of 72, so these figures are floors.

By year and ingredient

2020at least $1,202,266No dataat least $20,895,490at least $2,186,105at least $7,916,909at least $23,563at least $16,478at least $32,240,811
2021at least $2,923,629No dataat least $32,750,184at least $3,211,435at least $4,792,232$50,864at least $13,863at least $43,742,208
2022at least $7,809,544at least $300,503at least $46,492,251at least $5,098,616at least $2,433,132$49,133at least $23,175at least $62,206,353
2023at least $16,092,018at least $3,768,196at least $60,341,029at least $5,785,942at least $2,813,462$49,375Suppressedat least $88,850,023
2024at least $24,792,562at least $9,943,927at least $32,995,688at least $4,187,078at least $8,488,659$53,634Suppressedat least $80,461,548
2025at least $31,361,013at least $25,182,823at least $19,320,807at least $3,700,878at least $3,051,268at least $36,422Suppressedat least $82,653,211
2026 (Q1)at least $9,255,162at least $11,105,752at least $3,666,539at least $868,376$37,242SuppressedSuppressedat least $24,933,072

By product, 2025

Ozempicat least $27,986,369at least 28,3203 of 27
Rybelsusat least $1,781,386at least 1,6299 of 21
Wegovyat least $1,593,258at least 1,2151 of 20
Mounjaroat least $22,795,527at least 21,68223 of 55
Zepboundat least $2,387,296at least 2,24713 of 29
Liraglutide (generic name listing)at least $18,754,729at least 47,6735 of 49
SaxendaSuppressedSuppressed1 of 1
Victozaat least $566,078at least 87911 of 16
Trulicityat least $3,700,878at least 3,77917 of 36
Bydureonat least $2,803,301at least 3,4313 of 6
Byettaat least $192,742at least 2285 of 7
Exenatide (generic name listing)at least $55,225at least 772 of 6
Soliquaat least $36,422at least 421 of 4
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $22,662,442at least 29,44718 of 59
Q2 2025at least $18,837,994at least 25,34831 of 75
Q3 2025at least $19,673,378at least 27,08825 of 73
Q4 2025at least $21,479,397at least 29,31924 of 74

By quarter, 2026 (posted so far)

Q1 2026at least $24,933,072at least 30,84122 of 72

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.